Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Immunogenic properties of nickel-doped maghemite nanoparticles and the implication for cancer immunotherapy

L. Rajsiglova, M. Babic, K. Krausova, P. Lukac, K. Kalkusova, P. Taborska, L. Sojka, J. Bartunkova, D. Stakheev, L. Vannucci, D. Smrz

. 2024 ; 21 (1) : 2416988. [pub] 20241101

Language English Country England, Great Britain

Document type Journal Article

Nanoparticles are commonly used in diagnostics and therapy. They are also increasingly being implemented in cancer immunotherapy because of their ability to deliver drugs and modulate the immune system. However, the effect of nanoparticles on immune cells involved in the anti-tumor immune response is not well understood. The study reported here showed that nickel-doped maghemite nanoparticles (FN NP) are differentially cytotoxic to cultured mouse and human cancer cell lines, causing their death without negatively impacting the subsequent anticancer immune response. It also found that FN NP induced cell death in the mouse colorectal cancer cell line CT26 and human prostate cancer cell line PC-3, but not in the human prostate cancer cell line LNCaP. The induced cancer cell death did not affect the phenotype and responsivity of the isolated mouse peritoneal macrophages, or ex vivo-generated mouse bone marrow-derived, or human monocyte-derived dendritic cells. Additionally, the induced cancer cell death did not prevent the ex vivo-generated mouse or human dendritic cells from stimulating lymphocytes and enriching cell cultures with cancer cell-reactive T-cells. In conclusion, this study shows that FN NP could be a valuable platform for targeting cancer cells without causing immunosuppressive effects on the subsequent anticancer immune response.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003183
003      
CZ-PrNML
005      
20250206104105.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/1547691X.2024.2416988 $2 doi
035    __
$a (PubMed)39484726
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rajsiglova, Lenka $u Laboratory of Immunotherapy, Institute of Microbiology of the Czech Academy of Sciences, v.v.i, Prague, Czech Republic $u Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic
245    10
$a Immunogenic properties of nickel-doped maghemite nanoparticles and the implication for cancer immunotherapy / $c L. Rajsiglova, M. Babic, K. Krausova, P. Lukac, K. Kalkusova, P. Taborska, L. Sojka, J. Bartunkova, D. Stakheev, L. Vannucci, D. Smrz
520    9_
$a Nanoparticles are commonly used in diagnostics and therapy. They are also increasingly being implemented in cancer immunotherapy because of their ability to deliver drugs and modulate the immune system. However, the effect of nanoparticles on immune cells involved in the anti-tumor immune response is not well understood. The study reported here showed that nickel-doped maghemite nanoparticles (FN NP) are differentially cytotoxic to cultured mouse and human cancer cell lines, causing their death without negatively impacting the subsequent anticancer immune response. It also found that FN NP induced cell death in the mouse colorectal cancer cell line CT26 and human prostate cancer cell line PC-3, but not in the human prostate cancer cell line LNCaP. The induced cancer cell death did not affect the phenotype and responsivity of the isolated mouse peritoneal macrophages, or ex vivo-generated mouse bone marrow-derived, or human monocyte-derived dendritic cells. Additionally, the induced cancer cell death did not prevent the ex vivo-generated mouse or human dendritic cells from stimulating lymphocytes and enriching cell cultures with cancer cell-reactive T-cells. In conclusion, this study shows that FN NP could be a valuable platform for targeting cancer cells without causing immunosuppressive effects on the subsequent anticancer immune response.
650    _2
$a zvířata $7 D000818
650    _2
$a lidé $7 D006801
650    12
$a nikl $x chemie $x imunologie $7 D009532
650    _2
$a myši $7 D051379
650    12
$a imunoterapie $x metody $7 D007167
650    12
$a dendritické buňky $x imunologie $7 D003713
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a nádory prostaty $x imunologie $x terapie $7 D011471
650    _2
$a železité sloučeniny $x chemie $7 D005290
650    _2
$a nádory $x imunologie $x terapie $7 D009369
650    _2
$a buňky PC-3 $7 D000078722
655    _2
$a časopisecké články $7 D016428
700    1_
$a Babic, Michal $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Krausova, Katerina $u Laboratory of Immunotherapy, Institute of Microbiology of the Czech Academy of Sciences, v.v.i, Prague, Czech Republic $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Lukac, Pavol $u Laboratory of Immunotherapy, Institute of Microbiology of the Czech Academy of Sciences, v.v.i, Prague, Czech Republic $u Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Kalkusova, Katerina $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Taborska, Pavla $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Sojka, Ludek $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic $u Department of Technical Operations, SOTIO, a.s., Prague, Czech Republic
700    1_
$a Bartunkova, Jirina $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Stakheev, Dmitry $u Laboratory of Immunotherapy, Institute of Microbiology of the Czech Academy of Sciences, v.v.i, Prague, Czech Republic $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Vannucci, Luca $u Laboratory of Immunotherapy, Institute of Microbiology of the Czech Academy of Sciences, v.v.i, Prague, Czech Republic
700    1_
$a Smrz, Daniel $u Laboratory of Immunotherapy, Institute of Microbiology of the Czech Academy of Sciences, v.v.i, Prague, Czech Republic $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
773    0_
$w MED00188773 $t Journal of immunotoxicology $x 1547-6901 $g Roč. 21, č. 1 (2024), s. 2416988
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39484726 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104100 $b ABA008
999    __
$a ok $b bmc $g 2263122 $s 1239190
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 21 $c 1 $d 2416988 $e 20241101 $i 1547-6901 $m Journal of immunotoxicology $n J Immunotoxicol $x MED00188773
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...